HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

A Phase Ib Clinical Study on the Efficacy, Safety, Tolerability, and Pharmacokinetics of HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.

This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Study Overview

• Status: Recruiting
• Conditions: Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
• Intervention / Treatment: Drug: HS-20093 for injection

Detailed Description

The first approximately 20 eligible participants who meet the inclusion criteria and do not meet the exclusion criteria will receive intravenous infusion of 8.0 mg/kg HS-20093 once every three weeks (Q3W). Treatment will continue until objective disease progression or other treatment discontinuation criteria are met.

Based on preliminary safety, efficacy, and pharmacokinetic data, the sponsor may decide whether subsequent participants will continue the current dosing regimen (8.0 mg/kg, Q3W), switch to a lower dose (e.g., 6.0 mg/kg, Q3W), a higher dose (e.g., 10.0 mg/kg, Q3W), or transition to a dosing frequency of once every two weeks (with a single dose not exceeding 6.0 mg/kg).

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200032
      • Recruiting
      • ZhongShan Hospital FuDan University
      • Contact: Tianshu Liu, MD; Phone Number: 13681973996; Email: liu.tianshu@zs-hospital.sh.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. At least age of 18 years at screening, with no restrictions on gender.
2. Signed and dated Informed Consent Form.
3. Participants with pathologically or cytologically confirmed locally advanced unresectable or metastatic GC/GEJC, who have failed, or intolerant to standard therapies.
4. At least one extra measurable lesion according to RECIST 1.1.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1.
6. Estimated life expectancy >12 weeks.
7. Agree to provide fresh or archival tumor tissue.
8. Good organ function.
9. Female subjects must not be pregnant at screening or have evidence of non-childbearing potential.
10. Men or women should be using adequate contraceptive measures throughout the study.

Exclusion Criteria:

1. Treatment with any of the following:

   • Previous or current treatment with B7-H3 targeted therapy.
   • Previous or current treatment with topoisomerase I inhibitors.
   • Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
   • Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
   • Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
   • Treatment with drugs that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
   • Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study.
2. Histology shows squamous cell carcinoma, undifferentiated carcinoma, or mixed tumors , such as adenosquamous carcinoma or other mixed tumors.
3. Any unresolved toxicities from prior therapy greater than Grade 1 according to CTCAE 5.0 or baseline status.
4. Presence of pleural effusion/ascites requiring clinical intervention.
5. Newly diagnosed brain metastases without treatment, or brain metastases that have not achieved stability despite treatment; presence of leptomeningeal metastasis or brainstem metastasis; presence of spinal cord compression.
6. History of other primary malignancies
7. Evidence of cardiovascular risk.
8. Severe, uncontrolled or active cardiovascular diseases.
9. Severe or poorly controlled hypertension.
10. Severe or poorly controlled diabetes.
11. Poorly controlled cancer-related pain.
12. The presence of active infectious diseases has been known: hepatitis B, hepatitis C and HIV.
13. Major surgery within 4 weeks prior to the first scheduled dose of HS-20093.
14. Active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to the first dose.
15. Clinically significant bleeding symptoms or marked hemorrhagic tendency within 1 month prior to the first dose of HS-20093.
16. Serious arterial or venous thromboembolic events occurring within 3 months prior to the first dose of HS-20093.
17. Active tuberculosis.
18. History of known interstitial pneumonia or immune-mediated pneumonitis.
19. History of active or prior autoimmune disease requiring systemic treatment.
20. Severe malnutrition.
21. Current hepatic encephalopathy, hepatorenal syndrome, or cirrhosis ≥ Child-Pugh class B.
22. Requires long-term glucocorticoid therapy.
23. Having undergone any major surgery within 4 weeks prior to the first dose.
24. Vaccination within 4 weeks prior to the first dose of HS-20093.
25. History of severe allergy.
26. Previous history of serious neurological or mental disorders. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.
27. Currently enrolled in or participating in any other clinical study involving investigational interventions or other types of interventional medical research.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HS-20093; Participants will receive HS-20093	Drug: HS-20093 for injection; Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.	ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigators based on RECIST version 1.1[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)]	From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS assessed by RECIST 1.1 criteria	PFS was defined as the time from first dose or random assignment (if any) to PD or death from any cause	From the first dose up to PD or death，whichever came first, assessed up to 24 months.
Unconfirmed ORR (uORR)	The proportion of participants who achieve a CR or PR as assessed by the investigator according to the RECIST v1.1 criteria	From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.
Duration of response (DoR)	the time from the date of first documented objective response (CR or PR as assessed by the investigator according to the RECIST v1.1 criteria) to the date of first documented PD or death (whichever occurs first).	From the first dose up to PD or death, whichever came first, assessed up to 24 months.
Incidence and severity of adverse events (AEs)	AE assessed by investigator exclusively related to subject's underlying disease or medical condition [graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0]. Any untoward medical occurrence in a clinical study participant, whether or not considered related to the medicinal product. Incidence and severity of AEs are assessed according to vital signs, laboratory variables, physical examination, electrocardiogram, etc.	From the first dose until 90 days after the last dose
Cmax of HS-20093	The Cmax is the maximum observed drug concentration of HS-20093	At the end of Cycle 1 (each cycle is 21 days)"
Tmax of HS-20093	The Tmax is defined as time to reach maximum observed drug concentration of HS-20093	At the end of Cycle 1 (each cycle is 21 days)"
AUC0-t of HS-20093	The AUC0-t is defined as the area under the drug concentration-time curve during a dose interval time period(t) of HS-20093	At the end of Cycle 1 (each cycle is 21 days)"
Incidence of anti-hs-20093 antibodies (ADAs)	Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points	From the first dose until 90 days after the last dose

Collaborators and Investigators

• Sponsor: Hansoh BioMedical R&D Company

Study record dates

Study Major Dates

• Study Start (Actual): January 29, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): March 31, 2028

Study Registration Dates

• First Submitted: January 15, 2026
• First Submitted That Met QC Criteria: March 6, 2026
• First Posted (Actual): March 10, 2026

Study Record Updates

• Last Update Posted (Actual): March 10, 2026
• Last Update Submitted That Met QC Criteria: March 6, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: HS-20093; Gastric and Gastroesophageal Junction Adenocarcinoma
• Additional Relevant MeSH Terms: Therapeutics; Drug Administration Routes; Drug Therapy; Injections
• Other Study ID Numbers: HS-20093-109

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No